Navigation Links
Second Phase III Study of Avastin in 1st Line Metastatic Breast Cancer Meets its Primary Endpoint
Date:2/12/2008

- Results of This Trial Further Confirm the Benefit Avastin Brings to

Patients With Breast Cancer.

BASEL, Switzerland, Feb. 13 /PRNewswire/ -- Roche announced today that a phase III study in metastatic breast cancer investigating Avastin (bevacizumab) in combination with docetaxel chemotherapy compared to docetaxel alone, met its primary endpoint of improving the time patients live without their disease advancing.

The findings come from the first analysis of the phase III "Avastin and Docetaxel" ("AVADO", BO17708) study which investigated the addition of docetaxel to Avastin administered either at 7.5 or 15 mg/kg every 3 weeks. Both doses of Avastin in combination with chemotherapy showed statistically significant improvements in the time patients live without their disease advancing, as measured by progression-free survival, compared to chemotherapy alone. The study was not designed to compare the two Avastin-containing arms.

No new safety signals related to Avastin were observed in the trial.

Dr David Miles, medical oncologist, Mount Vernon Hospital, UK and principal investigator of AVADO, welcomed the news: "Each year more than one million women are diagnosed with breast cancer leading to over 400,000 deaths globally. This study confirms Avastin's effect of prolonging the time in which patients live without their disease getting worse in combination with a widely used chemotherapy partner -- this time gained is very precious."

The efficacy and safety data of AVADO will be presented at an upcoming medical meeting.

This second positive phase III trial follows the recently published landmark E2100 study, which formed the basis of European Commission approval of Avastin in combination with paclitaxel for the 1st line treatment of metastatic breast cancer in March 2007. Study E2100 showed that the addition of Avastin to paclitaxel resulted in a doubling of progression-free survival compared to paclitaxel alone.

About the BO17708 study

BO17708 is an international phase III trial which randomized 736 patients who did not receive previous chemotherapy for their metastatic breast cancer to one of three groups;

-- Avastin 7.5 mg/kg every 3 weeks in combination with docetaxel

-- Avastin 15 mg/kg every 3 weeks in combination with docetaxel

-- docetaxel + placebo as control arm

The primary objective of the study was to demonstrate superiority in progression-free survival of both Avastin containing treatment arms compared to the control arm. Secondary endpoints for the study included overall survival, response rate, duration of response, quality of life, safety and tolerability.

About Avastin

Data from the comprehensive Avastin cancer clinical development programme have resulted in approvals in advanced colorectal, breast, lung, and kidney cancer:

-- February 2004 (US) and January 2005 (EU) -- first-line treatment in

patients with metastatic colorectal cancer (CRC).

-- June 2006 (US) -- second-line treatment in patients with metastatic

CRC.

-- October 2006 (US) -- first-line treatment in patients with advanced

non-small cell lung cancer (NSCLC).

-- March 2007 (EU) -- first-line treatment in patients with metastatic

breast cancer.

-- April 2007 (Japan) -- treatment in patients with recurrent or advanced

CRC.

-- August 2007 (EU) -- first-line treatment in patients with advanced

NSCLC.

-- December 2007 (EU) -- first-line treatment in patients with advanced

RCC.

-- January 2008 (EU) -- first and later-line treatment in patients with

metastatic CRC in combination with any chemotherapy.

All trademarks used or mentioned in this release are legally protected.

Additional information

To access video clips about Avastin, in broadcast standard, free of charge, please go to: http://www.thenewsmarket.com.


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. Second Thoughts about Fluoride, Reports Scientific American
5. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
6. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
7. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
8. Immtech Reports Fiscal Second Quarter 2008 Results
9. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
10. Rcadias COR Analyzer Family of Products Receives Second FDA Clearance
11. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Inc. ("Hill-Rom") (NYSE: HRC ) today ... ended March 31, 2017, and raised its outlook ... guidance reflect the contribution from the Mortara Instrument ... 14, 2017.  For the fiscal second ... share compared to $0.33 per diluted share in ...
(Date:4/26/2017)... 2017 Phoenix Marketing Solutions ( Phoenix ... its mission of transforming science into clinical practice. During a ... Phoenix,s innovative approach supports the life sciences industry ... advances in science and medicine — which ultimately improves lives. ... in 2002 by Tracy Doyle and Angela ...
(Date:4/25/2017)... DUBLIN, Ohio , April 25, 2017 Endo International ... results on May 9, 2017. Members of its senior management team ... markets open at 8:30 a.m. ET. The dial-in ... (866) 497-0462, International (678) 509-7598, and the passcode is 6086379. Please ... A replay of the call will ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading provider ... Online(TM), which enables sleep physicians to create and edit their interpretation reports. This ... provides a familiar interface that does not require additional training to use. It ...
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... ... Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven one- ...
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
Breaking Medicine News(10 mins):